Everolimus (Afinitor)

mTOR inhibitor (protein kinase inhibitor); antineoplastic agent

Everolimus (Afinitor)

Forms and strengths
Form: TabletStrength: 2.5 mg, 5 mg, 10 mg (tablets); 2 mg, 3 mg, 5 mg (tablets for oral suspension)
Print

Indication

  • Everolimus (Afinitor) is used with exemestane to treat hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women whose cancer has progressed after treatment with letrozole or anastrozole.
  • Everolimus is used to treat advanced neuroendocrine tumours of the pancreas that cannot be surgically removed or have spread.
  • Everolimus is used to treat advanced, well-differentiated neuroendocrine tumours of the gastrointestinal tract or lung that have progressed.
  • Everolimus is used to treat advanced kidney cancer (renal cell carcinoma) after other targeted therapies have stopped working.
  • Everolimus is used to treat kidney angiomyolipoma (a type of benign tumour) associated with tuberous sclerosis complex (TSC) that does not require immediate surgery.
  • Everolimus (Afinitor) and its oral suspension form (Afinitor Disperz) are both used to treat subependymal giant cell astrocytoma (SEGA), a brain tumour associated with TSC.
  • Afinitor Disperz specifically is also used as an add-on treatment for seizures associated with TSC that are not well controlled with other therapies.
  • Everolimus is not recommended for functional carcinoid tumours, since a clinical trial did not show a clear benefit in this specific tumour type.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.